An emerging body of evidence is showing psychedelics as promising treatments for mental health conditions, and psychiatry needs to be prepared for their arrival, say researchers.
A low-cost version of ketamine has shown promising results in its treatment of resistant depression in a double-blind trial.
With an explosion in research looking at psychedelic therapy for a number of mental health conditions, FDA approval for MDMA-assisted psychotherapy for PTSD is anticipated for...
In what marks a positive development for patient access to psychedelic therapies in the US, the American Medical Association has released the language of its first-ever...
Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
COMPASS Pathways and MAPS Public Benefit Corporation (PBC) have put forward a joint application for a new code to facilitate access to psychedelic therapies in the...
Timmy Davis of the Conservative Drug Policy Reform Group (CDPRG) tells Psychedelic Health about the organisation’s campaign to reschedule psilocybin in a bid to increase psychedelic...
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
Lucy Scientific Discovery is partnering with non-profit organization that advocates for legal access to psilocybin therapy for Canadians, TheraPsil, to advance medical access and research.
Regulatory approvals for psychedelic medicines are becoming a reality, and the focus in policy and advocacy work is shifting from “if” to “when” and – most...
